Celia Dominguez
Reproductive Endocrinology · Honolulu, HINPI 1508895210
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (54.5%), speaking fees and education — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by AbbVie at 56.5% of the total. Reporting peaked in 2021 at $4,989 and has fallen 96.0% since, to $201 in 2025.
Across 161 payments — averaging $52.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$5K
- Ferring Pharmaceuticals Inc.$564
- Biohaven Pharmaceuticals, Inc.$471
- Covidien LP$408
- Organon$345
- Hologic Sales And Service, LLC$331
- plus $2K from 19 others
What the payments were for
- Speaking & faculty fees$3,82545%
- Food & beverage$4,62955%
- Education$320%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 42 | $4,796 |
| Ferring Pharmaceuticals Inc. | 20 | $564 |
| Biohaven Pharmaceuticals, Inc. | 12 | $471 |
| Covidien LP | 4 | $408 |
| Organon | 21 | $345 |
| Hologic Sales And Service, LLC | 4 | $331 |
| Amarin Pharma, Inc. | 6 | $292 |
| Merck | 16 | $280 |
| EMD Serono, Inc. | 4 | $146 |
| Roche Diagnostics Corporation | 4 | $135 |
| Exeltis, USA Inc. | 6 | $120 |
| Aspira Women's Health Inc | 4 | $112 |
| Gen-probe Sales & Service, Inc. | 1 | $102 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $54 |
| Myovant Sciences Inc. | 2 | $43 |
| Pacira Pharmaceuticals Incorporated | 1 | $42 |
| Sumitomo Pharma America, Inc. | 2 | $39 |
| Therapeuticsmd, Inc. | 2 | $36 |
| Astellas Pharma US Inc | 1 | $29 |
| Myriad Genetic Laboratories, Inc. | 1 | $28 |
| Sanofi Pasteur Inc. | 1 | $26 |
| Lilly USA, LLC | 1 | $25 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $25 |
| Bayer | 1 | $21 |
| Merz North America, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ORIAHNN$3,825
- NURTEC ODT$354
- TruClear$244
- Myosure$146
- Omniscope$146
- Aquilex$146
- Fetal Fibronectin$125
- AbsorbaTack$120
- Vascepa$118
- Orilissa$117
- Aptima$102
How this compares
Too few reproductive endocrinology providers in Hawaiito place this figure against a meaningful peer group, so we don't.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ProgesteroneProgesterone, Micronized | 11 | $1,040 |
Paid to pharmacies, not to this prescriber.
Other reproductive endocrinology in Honolulu
- Anatte KarmonHonolulu$3K
- Emily GouletHonolulu$2K
- Christina ArnettHonolulu$2K
- Christopher HuangHonolulu$1K
- Chelsey KeolaHonolulu$321
- Jingwen HouHonolulu$131
- John FrattarelliKailua$16K
- Gary LevyTripler Army Medical Center$15K
- Meghan YamasakiTripler Amc$2K
- Richard LucidiTripler Amc$347
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.